| Idarucizumab for dabigatran reversal CV Pollack Jr, PA Reilly, J Eikelboom, S Glund, P Verhamme, ... New England Journal of Medicine 373 (6), 511-520, 2015 | 2034 | 2015 |
| Idarucizumab for Dabigatran Reversal—Full Cohort Analysis CV Pollack Jr, PA Reilly, J van Ryn, JW Eikelboom, S Glund, ... New England Journal of Medicine 377 (5), 431-441, 2017 | 1174 | 2017 |
| Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial JC Soria, E Felip, M Cobo, S Lu, K Syrigos, KH Lee, E Göker, ... The Lancet Oncology 16 (8), 897-907, 2015 | 500 | 2015 |
| Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor–resistant EGFR-mutant lung cancer with and without T790M mutations YY Janjigian, EF Smit, HJM Groen, L Horn, S Gettinger, DR Camidge, ... Cancer discovery 4 (9), 1036-1045, 2014 | 429 | 2014 |
| Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran CV Pollack Jr, PA Reilly, R Bernstein, R Dubiel, J Eikelboom, S Glund, ... Thrombosis and haemostasis 114 (07), 198-205, 2015 | 199 | 2015 |
| Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial M Schuler, JCH Yang, K Park, JH Kim, J Bennouna, YM Chen, C Chouaid, ... Annals of Oncology 27 (3), 417-423, 2015 | 161 | 2015 |
| Afatinib vs placebo as adjuvant therapy after chemoradiotherapy in squamous cell carcinoma of the head and neck: a randomized clinical trial B Burtness, R Haddad, J Dinis, J Trigo, T Yokota, L de Souza Viana, ... JAMA oncology 5 (8), 1170-1180, 2019 | 39 | 2019 |
| Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired … L Horn, S Gettinger, DR Camidge, EF Smit, YY Janjigian, VA Miller, ... Lung Cancer 113, 51-58, 2017 | 21 | 2017 |
| LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high … B Burtness, RI Haddad, J Dinis, JM Trigo Perez, T Yokota, LDS Viana, ... Journal of Clinical Oncology 35 (15_suppl), 6001-6001, 2017 | 18 | 2017 |
| Correct and logical causal inference for binary and time‐to‐event outcomes in randomized controlled trials Y Liu, B Wang, M Yang, J Hui, H Xu, S Kil, JC Hsu Biometrical Journal 64 (2), 198-224, 2022 | 14 | 2022 |
| An improved uniformly more powerful exact Fisher–Hayter pairwise comparisons procedure B Wang, X Cui Biometrical Journal 59 (4), 767-775, 2017 | 7 | 2017 |
| General solutions to consistency problems in multiple hypothesis testing H Zhao, B Wang, X Cui Biometrical Journal 52 (6), 735-746, 2010 | 7 | 2010 |
| Sample size determination with familywise control of both type I and type II errors in clinical trials B Wang, N Ting Journal of Biopharmaceutical Statistics 26 (5), 951-965, 2016 | 6 | 2016 |
| An Application of Graphical Approach to Construct Multiple Testing Procedures in a Hypothetical Phase III Design B Wang, N Ting Frontiers in public health 1 (75), 1-6, 2014 | 6 | 2014 |
| Rejoinder for discussions on correct and logical causal inference for binary and time‐to‐event outcomes in randomized controlled trials Y Liu, B Wang, H Tian, JC Hsu Biometrical Journal 64 (2), 246-255, 2022 | 4 | 2022 |
| Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Analytics: Selected Papers from the 2015 ICSA/Graybill Applied Statistics … J Lin, B Wang, X Hu, K Chen, R Liu Springer, 2016 | 4* | 2016 |
| A new partition testing strategy for multiple endpoints B Wang, X Cui Statistics in medicine 31 (20), 2151-2168, 2012 | 2 | 2012 |
| Statistical Principles for Platform Trials X Cui, Y Liu, J Schneider, H Tian, B Wang, JC Hsu arXiv preprint arXiv:2302.12728, 2023 | 1 | 2023 |
| Consonant closed likelihood ratio test procedures with application to dose–response study B Wang, X Cui Statistics in medicine 29 (25), 2617-2630, 2010 | 1 | 2010 |
| Multiple Endpoints B Wang Handbook of Multiple Comparisons, 293-309, 2021 | | 2021 |
